Curium strikes up to $8 billion deal for Lantheus

Curium has entered into an agreement to acquire Lantheus in a transaction valued at up to $8 billion. The deal marks a significant consolidation within the healthcare and radiopharmaceutical sector, involving two major entities in the industry.

The acquisition represents a substantial financial commitment and is expected to impact the competitive landscape of the market. Both companies are currently aligning their operations to facilitate the transition as they move toward finalizing the terms of the agreement.